MedPath

New Service Protocol for Attention Deficit/Hyperactivity Disorder With Comorbidity: A Randomized Waitlist-controlled

Not Applicable
Recruiting
Conditions
ADHD
Interventions
Other: ADHD+
Registration Number
NCT05071066
Lead Sponsor
The University of Hong Kong
Brief Summary

The proposed study is to be carried out in 2021 - 2024 with youths aged 6 - 15 in Hong Kong. This is a randomized waitlist-controlled trial that aims to examine the effectiveness of the ADHD+ new service protocol. This ADHD+ new service protocol intervention will be delivered for 6 months in the format of groups by frontline social workers trained by professional clinicians including clinical psychologists and psychiatrists. It is designed to reduce ADHD and related symptoms in individuals aged between 6 and 15 years.

Core treatment components include internet use/addiction intervention, cognitive training, emotion management, social skills training, occupational training, emotion support/befriending, parenting training, and career guidance. It is hypothesized that youths receiving the intervention will have reduced ADHD and related symptoms when compared with controls.

Findings will allow the investigators to better understand the effectiveness of the new ADHD+ service; and in the long run, the service model can be generalized to community based early interventions for other uncomplicated mental disorders.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • children, adolescent and young adults (Aged 6-15);
  • have sufficient proficiency in Chinese to understand verbal instructions and give informed consent;
  • clinically significant mild to moderate ADHD syndromes requiring intervention;
  • without learning disabilities and intelligence quotient (IQ) score not lower than 70;
  • are "more likely to commit time in the projects" for reasons such as intention to treat and
  • receiving the New ADHD+ service.
Read More
Exclusion Criteria
  • known diagnosis of intellectual disability;
  • not reaching syndrome diagnostic threshold for ADHD;
  • already receiving medical interventions / treatments at Hospital Authority (HA) and/or private sector;
  • known psychiatric diagnosis (stabilized diagnosis and treatment);
  • current or active suicidal ideation or attempts;
  • have received structured psychosocial intervention for more than 3 contact hours (for waitlist group); and
  • refusal to give consent.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
wait-list control groupADHD+For participants in the waiting list control group, they will receive 1-3 hours psychoeducation during the 3 months wait period. Appropriate intervention will be offered after the treatment group.
Group-based ADHD+ TreatmentADHD+This randomized controlled trial (RCT) will run in multi-sites including 5 non-governmental organizations (NGOs) in Hong Kong. Core treatment components are developed by an expert group comprised of psychiatrists and clinical psychologists including internet use/addiction intervention, cognitive training, etc. The main intervention lasts for 3 months, and the booster intervention lasts for another 3 months.
Primary Outcome Measures
NameTimeMethod
The change of overall ADHD and related symptomsFrom Time 0 (Baseline) to Time 1 (post-intervention 3-month) to Time 2 (post-intervention 6-month)

Measured by Strengths and Weaknesses of ADHD-symptoms and Normal-behaviors questionnaire (SWAN) (for service users under 18 years old) (parent report). The scale has 18 items, each rated from -3 to 3 following 7-point Likert scale. Higher scores indicate greater symptomology

The change of difficult behavior in service usersFrom Time 0 (Baseline) to Time 1 (post-intervention 3-month) to Time 2 (post-intervention 6-month)

Measured by Strengths and Difficulties Questionnaires (SDQ) \[children version\]. The scale has 25 items, each rated from 0 - 2. Higher score indicate more difficult behaviors.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Hong Kong

🇭🇰

Hong Kong, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath